Oculis Holding AG (OCS) Long-Term Deferred Tax (2022 - 2024)
Oculis Holding AG (OCS) posted quarterly Long-Term Deferred Tax of $342456.6 for Q4 2024, up 590.39% year-over-year from $49603.6 in Q1 2024, and up 590.39% quarter-over-quarter from $49603.6 in Q4 2023.
Powered by 
Analysis
Oculis Holding AG (OCS) Long-Term Deferred Tax (2022 - 2024) Analysis & Trends
Oculis Holding AG's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $342456.6 for Q4 2024.
- In Q4 2024, Long-Term Deferred Tax rose 590.39% year-over-year to $342456.6; the TTM figure through Dec 2024 stood at $342456.6 (up 590.39% YoY), while the FY2024 annual figure was $341010.4, up 596.06% from the prior year.
- Long-Term Deferred Tax for Q4 2024 stood at $342456.6, up from $49603.6 in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $342456.6 in Q4 2024, with the low at $49603.6 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 342,456.55 |
| Dec 31, 2023 | 49,603.60 |
| Dec 31, 2022 | 24,912.53 |